Victoza-Tresiba Drug Combo Worries FDA Reviewers

FDA reviewers are questioning clinical trial data that suggests a combination of the diabetes drugs Victoza and Tresiba is more effective than using Tresiba alone. 

In preparation for an FDA advisory panel meeting on May 24, the reviewers released a report (PDF) that expresses concerns over the clinical trials Novo Nordisk conducted, which showed that its combination drug Xultophy, already on the market in Europe, was more effective than Tresiba alone.

Victoza (liraglutide) is an injectable diabetes drug introduced by Novo Nordisk in 2010, as a competitor to Byetta. Tresiba (insulin degludec) is a long-acting form of insulin approved last year. Together, the two are referred to as IDegLira here in the U.S., as the combination does not yet have a brand name here.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The FDA reviewers raised questions about combining the two drugs, which work very differently. One concern was that the proposed dosage of Victoza is below the dose usually considered effective when Victoza is used alone. The reviewers warned that some sensitive patients “could be exposed to one component that provides no therapeutic benefit and causes specific adverse reactions.”

“As was seen in the IDegLira program, subjects randomized to IDegLira experienced adverse events caused by both of its components, namely subjects experienced gastrointestinal adverse events (liraglutide) and hypoglycemia (insulin degludec),” the reviewers warned. “Further, the use of IDegLira allows for doses of liraglutide lower than that approved for glycemic lowering, and a patient may be exposed to a dose of liraglutide that has not been studied in phase 3 trials and determined to be efficacious while incurring safety risks associated with liraglutide use.”

They also questioned the design of the study, raising concerns that inadequate insulin dosing could have skewed the results.

The advisory panel will take the reviewers report, as well as other testimony and scientific evidence, into consideration and then recommend a course of action to the FDA. Novo Nordisk is trying to get the drug approved for the U.S. market.

The panel’s recommendations are not binding on the FDA, however, they usually factor heavily into the agency’s final decisions.

The concerns over a Victoza and Tresiba combination drug comes amid continuing concerns about the risk of pancreatic cancer, with a number of Victoza lawsuits pending in courts nationwide on behalf of former users who allege that Novo Nordisk failed to adequately warn consumers and the medical community. Similar allegations have been raised in claims involving other diabetes drugs from the same class of medications, including Byetta lawsuits, Januvia lawsuits and Janumet lawsuits, alleging that the entire incretin mimetic class of drugs increases the risk of pancreatic cancer for diabetics.

Image Credit: |

1 Comments

  • ETHELSeptember 24, 2020 at 10:01 pm

    Ok!! I am quite disturb now over my plan from my phy. due to my elevated A1C and bloodsugar results of 400 plus to 350.I was started on Tresebia and victorozia insulin with no s/sx of pancreatic disturbances or gastritis as well as glimpride daily that was not a help but added another illness that I do not need .just trying to pay for the medicine this a LOL minute paying for medications to gi[Show More]Ok!! I am quite disturb now over my plan from my phy. due to my elevated A1C and bloodsugar results of 400 plus to 350.I was started on Tresebia and victorozia insulin with no s/sx of pancreatic disturbances or gastritis as well as glimpride daily that was not a help but added another illness that I do not need .just trying to pay for the medicine this a LOL minute paying for medications to give you another kick in the ass

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL
Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL (Posted today)

Plaintiffs say a federal judge should not waste time on a phased discovery plan requiring them to first prove Suboxone strips can cause tooth decay, saying the science is obvious and such a plan could delay resolution of hundreds of product liability lawsuits.